stocks logo

CTXR

Citius Pharmaceuticals Inc
$
1.460
+0.02(1.389%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.490
Open
1.430
VWAP
1.45
Vol
390.82K
Mkt Cap
16.31M
Low
1.4009
Amount
568.46K
EV/EBITDA(TTM)
--
Total Shares
180.67M
EV
19.99M
EV/OCF(TTM)
--
P/S(TTM)
--
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
--
--
4.500
-446.15%
--
--
0.330
-105.69%
--
--
-0.210
-86%
Estimates Revision
The market is revising No Change the revenue expectations for Citius Pharmaceuticals, Inc. (CTXR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 73.40%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-6.47%
In Past 3 Month
Stock Price
Go Up
up Image
+73.40%
In Past 3 Month
3 Analyst Rating
up Image
242.47% Upside
Wall Street analysts forecast CTXR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTXR is 5.00 USD with a low forecast of 4.00 USD and a high forecast of 6.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
up Image
242.47% Upside
Current: 1.460
sliders
Low
4.00
Averages
5.00
High
6.00
D. Boral Capital
D. Boral Capital
Buy
downgrade
$9 -> $6
2025-06-10
Reason
D. Boral Capital lowered the firm's price target on Citius Pharmaceuticals to $6 from $9 and keeps a Buy rating on the shares. The firm cites dilution for the target cut after the company announced a registered direct offering totaling up to $15.8M in gross proceeds.
Maxim
Buy
to
Hold
downgrade
2025-05-23
Reason
Maxim downgraded Citius Pharmaceuticals to Hold from Buy.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-02-18
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-01-07
Reason
D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm believes that as Lymphir launches, it will become a value driver for its parent, Citius. Oncology drug Lymphir has achieved significant milestones in its development and approval process, contends D. Boral.
D. Boral Capital
Jason Kolbert
Hold
to
Strong Buy
Upgrades
$9
2024-12-30
Reason
D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm believes that as Lymphir launches, it will become a value driver for its parent, Citius. Oncology drug Lymphir has achieved significant milestones in its development and approval process, contends D. Boral.
D. Boral Capital
Jason Kolbert
Strong Buy
to
Hold
Downgrades
n/a
2024-11-22
Reason
D. Boral Capital downgraded Citius Pharmaceuticals to Hold from Buy without a price target following the company's announcement of a 1-for-25 reverse stock split. The reverse is partly a result of the failure of the spinoff of Citius Oncology to unlock shareholder value, the analyst tells investors in a research note. The firm says the downgrade is more technical than fundamental.

Valuation Metrics

The current forward P/E ratio for Citius Pharmaceuticals Inc (CTXR.O) is 0.89, compared to its 5-year average forward P/E of -5.68. For a more detailed relative valuation and DCF analysis to assess Citius Pharmaceuticals Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.68
Current PE
0.89
Overvalued PE
11.78
Undervalued PE
-23.14

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.46
Current PS
0.43
Overvalued PS
10.28
Undervalued PS
-1.37

Financials

Annual
Quarterly
FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY :
+2.65%
-11.26M
Operating Profit
FY2025Q2
YoY :
+34.73%
-11.51M
Net Income after Tax
FY2025Q2
YoY :
-5.22%
-1.27
EPS - Diluted
FY2025Q2
N/A
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CTXR News & Events

Events Timeline

2025-07-15 (ET)
2025-07-15
08:36:27
Citius Oncology signs distribution agreement for Lymphir with Cencora
select
2025-06-17 (ET)
2025-06-17
08:10:20
Citius Oncology expects commercial launch of Lymphir in second half of 2025
select
2025-06-10 (ET)
2025-06-10
07:05:25
Citius Pharmaceuticals announces $15.8M registered direct offering
select
Sign Up For More Events

News

8.5
07-17PRnewswire
Citius Oncology Announces Closing of $9.0 Million Public Offering
8.5
07-16Newsfilter
Citius Oncology Announces Pricing of $9.0 Million Public Offering
7.5
07-15Newsfilter
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Sign Up For More News

FAQ

arrow icon

What is Citius Pharmaceuticals Inc (CTXR) stock price today?

The current price of CTXR is 1.46 USD — it has increased 1.39 % in the last trading day.

arrow icon

What is Citius Pharmaceuticals Inc (CTXR)'s business?

arrow icon

What is the price predicton of CTXR Stock?

arrow icon

What is Citius Pharmaceuticals Inc (CTXR)'s revenue for the last quarter?

arrow icon

What is Citius Pharmaceuticals Inc (CTXR)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Citius Pharmaceuticals Inc (CTXR)'s fundamentals?

arrow icon

How many employees does Citius Pharmaceuticals Inc (CTXR). have?

arrow icon

What is Citius Pharmaceuticals Inc (CTXR) market cap?